H.R. 5247
IntroducedTrickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018
Latest Action
Read the second time. Placed on Senate Legislative Calendar under General Orders. Calendar No. 367.
4/9/2018 • Senate
Summary
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018
This bill amends the Federal Food, Drug, and Cosmetic Act to exempt, from specified requirements and restrictions under that Act and other laws, the provision of certain unapproved, investigational drugs to a terminally ill patient who has exhausted approved treatment options and is unable to participate in a clinical trial involving the drugs. The manufacturer or sponsor of an eligible investigational drug must publish annual summaries on any use of the drug in accordance with these provisions.
The bill limits the liability of a sponsor, manufacturer, licensed physician, clinical investigator, or hospital that provides, or declines to provide, an eligible investigational drug to an eligible patient in accordance with the bill.
Introduced in House • 3/13/2018
Topics & Subjects
Congressional Votes (3)
On Passage
March 21, 2018
On Motion to Recommit with Instructions
March 21, 2018
On Motion to Suspend the Rules and Pass
March 13, 2018
Related Federal Spending
Sponsor & Cosponsors (45)
Party Breakdown
Sponsor
Cosponsors (44)
Bill Journey
Originated in the House
Introduced
March 13, 2018
Committee Review
March 19, 2018
Floor Debate
March 13, 2018
Passed Chamber
March 13, 2018
Other Chamber
March 22, 2018
President
Failed
March 13, 2018
Text Versions (3)
Related Bills (2)
S. 204
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017
H.Res. 787
Providing for consideration of the bill (H.R. 4566) to amend the Dodd-Frank Wall Street Reform and Consumer Protection Act to provide relief to nonbanks from certain stress test requirements under such Act; providing for consideration of the bill (H.R. 5247) to authorize the use of eligible investigational drugs by eligible patients who have been diagnosed with a stage of a disease or condition in which there is reasonable likelihood that death will occur within a matter of months, or with another eligible illness, and for other purposes; and for other purposes.